Breakthrough clinical trials into new treatments for bone marrow and liver cancer will soon commence after experienced institutional biotech investors…
Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for…
Streamlining operations to focus on the most profitable side of their pharmaceuticals manufacturing business, Pharmaxis (ASX: PXS) has shored up…
In biotech circles, tackling a rare and difficult disease with few patients does not necessarily equate to targeting an unprofitable…